HCW Biologics Inc. (HCWB)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.41 |
Market Cap | 16.26M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.01 |
PE Ratio (ttm) | -0.43 |
Forward PE | n/a |
Analyst | Buy |
Ask | 0.45 |
Volume | 795,948 |
Avg. Volume (20D) | 15,939,563 |
Open | 0.44 |
Previous Close | 0.49 |
Day's Range | 0.40 - 0.48 |
52-Week Range | 0.21 - 2.52 |
Beta | undefined |
About HCWB
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata ...
Analyst Forecast
According to 1 analyst ratings, the average rating for HCWB stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.